Cytology for PD-L1 testing: a systematic review

Antibodies targeting the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway have improved outcomes for patients with advanced non-small-cell lung cancer (NSCLC), and are now approved in several countries [1 –7]. As improved clinical outcomes with these antibodies are often associated with higher tumor PD-L1 expression levels in NSCLC [1,3,7,8], different PD-L1 expression cutoffs have been investigated in clinical trials and as part of the co-development of immunohistochemistry (IHC) assays.

Source: Lung Cancer - January 12, 2020 Category: Cancer & Oncology Authors: John R. Gosney, Anne-Marie Boothman, Marianne Ratcliffe, Keith M. Kerr Source Type: research